[The immunological aspects of systemic enzyme therapy in the combined treatment of recurrent nephrolithiasis].
Results are submitted of treatment of 50 patients of different years of age, who were presenting with urolithiasis and concomitant chronic pyelonephritis, using methods of surgical treatment alone and in combination with a drug preparation of systemic enzymotherapy (SE) phlogenzyme. Based on the analysis of the findings obtained a conclusion has been drawn that the SE drug phlogenzyme is an effective medication for correction of disorders of the immune homeostasis in patients with urolithiasis and for prevention of recurrent lithogenesis after surgical interventions in kidneys and ureters.
A V
AV
Borisov
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D057487:Enzyme Therapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007669:Kidney Calculi / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D011704:Pyelonephritis / Q000150:complications; D012008:Recurrence
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents